Recent advances in theranostics and challenges for the future
JH Turner - The British journal of radiology, 2018 - birpublications.org
Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of
neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled …
neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled …
Hydrophilic small molecules that harness transthyretin to enhance the safety and efficacy of targeted chemotherapeutic agents
The hydrophobicity of many chemotherapeutic agents usually results in their nonselective
passive distribution into healthy cells and organs causing collateral toxicity. Ligand-targeted …
passive distribution into healthy cells and organs causing collateral toxicity. Ligand-targeted …
The five “w” s and “how” of targeted alpha therapy: why? who? what? where? when? and how?
Cancer is the second cause of death and morbidity in Europe. Unfortunately, currently
available treatments cannot permanently cure most cancers, especially when metastatic …
available treatments cannot permanently cure most cancers, especially when metastatic …
Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA
YA Ivanenkov, AE Machulkin, AS Garanina… - Bioorganic & medicinal …, 2019 - Elsevier
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II
(GCPII), has recently emerged as a prominent biomarker of prostate cancer (PC) and as an …
(GCPII), has recently emerged as a prominent biomarker of prostate cancer (PC) and as an …
Incorporating Glutamic Acid-Valine-Citrulline Linker in Trifunctional Molecules Targeting PSMA Ensures Enhanced Stability, Safety, and Efficacy in Mouse Model of …
TU Amin - 2022 - search.proquest.com
This project describes the development of a new antitumor therapeutic platform that
combines the benefits of small-molecule drug conjugates (SMDCs) and antibody drug …
combines the benefits of small-molecule drug conjugates (SMDCs) and antibody drug …
Development of a new class of ligand-targeted chemotherapeutics with enhanced safety and efficacy profile
A Pal - 2019 - scholarlycommons.pacific.edu
The hydrophobicity of many chemotherapeutic agents usually results in their nonselective
passive distribution into healthy cells and organs causing collateral toxicity. Ligand-targeted …
passive distribution into healthy cells and organs causing collateral toxicity. Ligand-targeted …